| Title: |
Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan. |
| Authors: |
Mitsumasa Kishimoto; Soliman, Ahmed M.; Nunag, Dominic; Lippe, Ralph; Patel, Manish; Davis, Matthew; Hideto Kameda |
| Source: |
Modern Rheumatology; May2026, Vol. 36 Issue 3, p430-438, 9p |
| Subject Terms: |
Psoriatic arthritis; Japanese people; Scientific observation; Antirheumatic agents; Termination of treatment; Therapeutics; Relative medical risk |
| Geographic Terms: |
Japan |
| Abstract: |
Objectives: To evaluate switching and discontinuation of biologic disease-modifying antirheumatic drugs (bDMARDs) among psoriatic arthritis (PsA) patients in Japan over 12 months. Methods: Claims data from the Japan Medical Data Centre (1/2005–10/2023) were analysed for patients with a PsA diagnosis on or before first bDMARD claim (index date) and ≥ 6 months of eligibility pre-index. Treatment switch (claim for another bDMARD) and discontinuation (treatment gap ≥150% days' supply of last prescription) were evaluated up to 12 months post-index. Hazard ratios for switching and discontinuation were estimated using multivariate Cox proportional hazards models adjusted for baseline characteristics. Results: Included patients received adalimumab (n = 323), brodalumab (n = 71), certolizumab pegol (n = 162), guselkumab (n = 157), ixekizumab (n = 239), risankizumab (n = 117), secukinumab (n = 250), or ustekinumab (n = 60). At 12 months, 21.7% switched bDMARDs and 38.1% discontinued their index bDMARD. Risankizumab had the lowest switching rate (18.4%), followed by secukinumab (19.1%) and ixekizumab (19.7%). Risankizumab had the lowest discontinuation rate (23.4%), followed by ustekinumab (27.6%) and ixekizumab (29.7%). Hazard ratios of switching and/or discontinuation were significantly higher for most bDMARDs (except ixekizumab, ustekinumab) versus risankizumab (P |
| : |
Copyright of Modern Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |